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factor A (v e g f a ), but is not discussed in this review. 
(It is not approved for use in advanced kidney cancer 
in Canada.)
2.1  Recommended Treatment Schedules and Dose 
Adjustments
2.1.1  Sunitinib
From the drug label 9, the starting dose for sunitinib 
is 50 mg orally once daily with or without food, in 
a 4-weeks-on, 2-weeks-off regimen. Standard dose 
modification in 12.5-mg steps is recommended. If 
more than 2 dose reductions are required, discontinu-
ation of therapy should be considered. Recovery to 
acceptable levels of toxicity must occur to allow suni-
tinib continuation. Re-escalation to the previous dose 
schedule can be considered in the absence of grade 
3 or greater hematologic toxicity, or in the absence 
of grade 2 or greater non-hematologic toxicity. The 
drug label recommends permanent discontinuation of 
sunitinib in the rare case of congestive heart failure, 
pancreatitis, or hepatic failure.
Clinical studies excluded patients with a serum 
creatinine in excess of 2 times the upper limit of 
normal (u l n ), and so caution is recommended in the 
presence of severe kidney impairment. No dose ad-
justment is required for Child–Pugh class A or B he-
patic impairment, but sunitinib has not been studied in 
severe (Child–Pugh class C) liver impairment. Clini-
cal studies excluded patients with aminotransferase 
levels in excess of 2.5 times the u l n  or, if a result of 
liver metastases, in excess of 5 times the u l n  9.
Based mostly on clinical experience and very 
limited data from early-phase clinical trials 10,11, al-
ternative regimens of sunitinib might be considered: 
either a 2-weeks-on, 1-week-off regimen, or continu-
ous daily dosing with 37.5 mg. However, efficacy 
confirmation for these latter regimens is lacking.
2.1.2  Sorafenib
The recommended dose of sorafenib is 400 mg orally 
twice daily without food (at least 1 hour before or 2 hours 
after a meal). When dose reduction is required, the 
dose may be reduced to 400 mg once daily, and further 
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1.  INTRODUCTION
Sunitinib, sorafenib, temsirolimus, and bevacizumab 
are new drugs used in treatment of advanced kidney 
cancer 1–4, together with another emerging agent, 
everolimus 5. By targeting healthy tissues, these drugs 
cause toxicities that can lead to delay, dose reduction, 
or discontinuation of the drug treatment. When such 
disruptions occur early on, the potential benefit to the 
patient of these new agents is lost.
The use of targeted agents in a less selected pa-
tient population outside of clinical trials can certainly 
be challenging, but experience to date shows that most 
of the toxicities associated with the new agents are 
manageable. The data about the toxicities of sunitinib 
and sorafenib outside of clinical trials in expanded-
access programs are reassuring 6,7. In the present 
review, we describe the recommended doses of the 
new drugs and the management of common toxicities 
of drugs used in advanced kidney cancer.
2.  INHIBITORS OF KINASES: SUNITINIB AND 
SORAFENIB
Sunitinib and sorafenib target tyrosine kinases, in-
cluding vascular endothelial growth factor receptors 
(v e g f r s) 8. The humanized monoclonal antibody 
bevacizumab inhibits vascular endothelial growth TARGETED DRUGS IN ADVANCED KIDNEY CANCER
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to 400 mg once every other day. An alternative, more 
gradual reduction is to use one dose of 200 mg while 
the second dose is maintained at 400 mg (600 mg daily 
total); reduction to 400 mg daily can then follow if 
toxicity persists.
Permanent discontinuation should be consid-
ered in the unlikely events of bleeding that requires 
medical intervention or of gastrointestinal perfora-
tion. Temporary interruption should be considered 
in patients undergoing major surgical procedures and 
in whom cardiac ischemia or infarction occur; in the 
latter setting, permanent discontinuation can be con-
sidered. No dose adjustment is necessary in patients 
with kidney impairment who are not undergoing 
dialysis (patients on dialysis have not been studied). 
Mild and moderate (Child–Pugh A and B) liver im-
pairment may reduce plasma levels of sorafenib, but 
the optimal dose of sorafenib in hepatic impairment 
has not been established 12.
2.2	 Drug	Metabolism	and	Dose	Modifications
Sunitinib and sorafenib are metabolized primarily 
by cytochrome P450 (CYP) 3A4 in the liver, and 
sorafenib additionally undergoes glucuronidation 
by uridine glucuronyl transferase 1A9 and by being 
a competitive inhibitor of CYP2B6 and CYP2C8 
isozymes 9,12. Concomitant use of medications that 
substantially affect these metabolizing enzymes 
should be avoided (Tables i and ii). The dose of suni-
tinib should be reduced to a minimum of 37.5 mg if 
strong CYP3A4 inhibitors must be co-administered 
and possibly increased to a maximum of 87.5 mg if 
strong CYP3A4 inducers must be co-administered 
(Table i ). Sorafenib seems not to have any clinically 
significant pharmacokinetic interactions with strong 
CYP3A4 inhibitors, but if a strong CYP3A4 inducer 
must be co-administered, an increase of the sorafenib 
dose should be considered 12.
t a b l e  i  Agents that interact with cytochrome P450 3A4
Stronga
Inhibitors
Moderateb Mildc
Inducers
h i v  antivirals
(indinavir, nelfinavir,
ritonavir)
Clarithromycin
Ketoconazole
Itroconazole
Nefazodone
Saquinavir
Telithromycin
Aprepitant
Fluconazole
Erythromycin
Verapamil
Diltiazem
Grapefruit juice
Cimetidine
Amiodarone
Norfloxacin
Voriconazole
Delaviridine
Fluvoxamine
Gestodene
Imatinib
Star fruit
h i v  antivirals
(efavirenz, nevirapine)
Barbiturates
Carbamazepine
Glucocorticoids
Modafinil
Nevirapine
Oxcarbazepine
Phenobarbital
Phenytoin
Pioglitazone
Rifabutin
Rifampin
Troglitazone
St. John’s Wort
Substrates
Macrolide antibiotics
(clarithromycin,  
erythromycin,
not azithromycin)
Anti-arrhythmics  
(quinidine)
Benzodiazepines
(midazolam, diazepam,
alprazolam, triazolam)
Immune modulators
(cyclosporine,
tacrolimus)
h i v  antivirals
(indinavir, nelfinavir,
ritonavir, saquinavir)
Antihistamines
(astemizole,
chlorpheniramine,
terfenadine)
Calcium channel blockers
(amlodipine, diltiazem,
nifedipine, verapamil)
Statins
(atorvastatin,  
cerivastatin,
lovastatin, simvastatin,
not pravastatin)
Steroids
(estradiol, hydrocortisone,
progesterone, testosterone)
Miscellaneous
(aprepitant, ondansetron,
caffeine, domperidone,
haloperidol, fentanyl,
lidocaine, propranolol,
salmeterol, quinine)
  
a  Increase by more than a factor of 5 in plasma area under the curve (a u c ) value, or more than 80% decrease in clearance.
b  Increase by more than a factor of 2 in plasma a u c  value, or 50%–80% decrease in clearance.
c  Increase by a factor of 2 or less in plasma a u c  value, or less than 50% decrease in clearance.
t a b l e  ii  Agents that interact with cytochrome P450 2B6 and cytochrome P450 2C8a
Strongb
Inhibitors
Moderatec Mildd
Inducers
Gemfibrozil Trimethoprim Ticlopidine, montelukast,
quercetin, glitazones
Rifampin Phenobarbital
Substrates
Bupropion
Paclitaxel
Cyclophosphamide
Torsemide
Efavirenz
Amodiaquine
Ifosfamide
Cerivastatin
Methadone
Repaglinide
  
a  Applicable to sorafenib only.
b  Increase by more than a factor of 5 in plasma area under the curve (a u c ) value, or more than 80% decrease in clearance.
c  Increase by more than a factor of 2 in plasma a u c  value, or 50%–80% decrease in clearance.
d  Increase by a factor of 2 or less in plasma a u c  value, or less than 50% decrease in clearance.SERUGA et al.
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2.3  Common Toxicities
The most commonly reported clinical toxicities are 
constitutional, gastrointestinal, hypertensive, and 
skin-related; the most common laboratory toxicities 
are lymphopenia, neutropenia, thrombocytopenia, 
anemia, elevated lipase, and hypophosphatemia 1,2. In 
pivotal randomized clinical trials (r c t s), severe—that 
is, grades 3 and 4—toxicities were reported in two 
thirds of patients on sunitinib 1 and in more than one 
third of patients on sorafenib 2.
3.  TEMSIROLIMUS
Temsirolimus is a potent, highly specific inhibitor of 
the mammalian target of rapamycin (mt o r ). It inhibits 
cell proliferation, cell growth, survival pathways, and 
tumour angiogenesis 13. Everolimus (RAD001) is an 
orally administered mt o r  inhibitor currently under 
review by Health Canada.
3.1  Recommended Treatment Schedule and Dose 
Adjustments
The recommended dose of temsirolimus in ad-
vanced kidney cancer is a flat dose of 25 mg infused 
over 30–60 minutes once weekly. Before each 
administration of temsirolimus, patients should 
receive intravenous (IV) H1 antihistamine—for 
example, IV diphenhydramine 25–50 mg 30 min-
utes before temsirolimus. If hypersensitivity oc-
curs, the infusion should be stopped for at least 
30–60 minutes and resumed at a slower rate ap-
proximately 30 minutes after IV administration of 
an H2 antihistamine—for example, IV famotidine 
20 mg or ranitidine 50 mg 14. If a severe hypersen-
sitivity reaction occurs, re-challenge with temsi-
rolimus is contraindicated.
Temsirolimus should be held in the presence 
of an absolute neutrophil count below 1000/µL, a 
platelet count below 75,000/µL, or any other grade 3 
or greater toxicity. Once toxic effects have resolved 
to grade 2 or lesser, temsirolimus can be restarted at 
20 mg or 15 mg weekly, but no lower. No data on 
dosing in patients with kidney and hepatic impair-
ment are available 14.
3.2	 Drug	Metabolism	and	Dose	Modifications
Temsirolimus is metabolized by CYP3A4, and 
strong inducers and inhibitors should not be co-
administered (Table i). If a strong CYP3A4 inhibi-
tor or inducer must be co-administered, the dose 
of temsirolimus should be reduced to 12.5 mg 
weekly or cautiously increased to 50 mg weekly 
respectively. If the strong CYP3A4 inhibitor is dis-
continued, a 1-week washout period should elapse 
before temsirolimus is re-instituted at the dose level 
previously used 14.
3.3  Common Toxicities
The most common clinical toxicities of temsiroli-
mus are constitutional and skin-related; the most 
common laboratory toxicities are hyperglycemia, 
hypertriglyceridemia, hypercholesterolemia, hy-
pophosphatemia, and hematologic toxicities. In a 
pivotal r c t, the most common severe toxicities were 
anemia (13%), hyperglycemia (9%), asthenia (8%), 
and hypertriglyceridemia (3%) 15. Rare but fatal 
cases of nonspecific interstitial pneumonitis have 
been reported in phase i and ii trials in patients with 
advanced kidney cancer on temsirolimus 16. Most 
temsirolimus-related toxicities can be managed 
medically or with supportive care without a need 
for interruption or dose reduction.
4.  MANAGEMENT OF TOXICITIES
4.1  Fatigue
Fatigue has been reported in 51% and 37% of pa-
tients on sunitinib and sorafenib respectively; severe 
fatigue occurred in 5%–7% of patients 1,2. In a r c t  
of sorafenib, patients with advanced kidney cancer 
on sorafenib did not experience significantly more 
fatigue than did patients on placebo 2.
Fatigue may be associated with hypothyroidism, 
anemia, depression, or dehydration, all of which 
can be addressed. Thyroid hormone replacement 
therapy benefited 50% of patients who developed 
overt hypothyroidism on sunitinib 17, indicating that 
other mechanisms causing fatigue are at play in these 
patients. Physical activity is effective in the manage-
ment of cancer-related fatigue 18, and patients should 
be counselled to do some light exercise, if appropriate. 
In severe fatigue, treatment should be interrupted and 
the dose reduced (Table iii).
4.2  Gastrointestinal Toxicity
4.2.1  Diarrhea
In r c t s, diarrhea occurred in 53% and 43% of patients 
on sunitinib and sorafenib respectively; severe diar-
rhea occurred in 2%–5% of patients 1,2.
Mild diarrhea (an increase of up to 6 stools daily 
over baseline) can be managed by oral hydration 
and antidiarrheal agents (for example, loperamide 
or diphenoxylate) alone. In severe diarrhea, patient 
should be hospitalized for IV hydration; treatment 
with sunitinib and sorafenib should be discontinued 
until diarrhea is grade 1 or stools have returned to 
baseline, when treatment can be restarted at a lower 
dose. During an episode of diarrhea patients should 
be counselled to avoid the use of stool softeners, laxa-
tives, antacids, and a fibre-rich diet. Other causes of 
diarrhea, such as antibiotics, infectious gastroenteritis, 
partial intestinal obstruction, and radiation-induced 
enteritis should be excluded (Table iii).TARGETED DRUGS IN ADVANCED KIDNEY CANCER
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t a b l e  iii  Summary of toxicities induced by anticancer drugs in kidney cancer, and related management strategies
Toxicity Management
Fatigue Exclude other possible causes of fatigue.
Light exercise is recommended (if appropriate).
If severe fatigue persists, interrupt treatment and reduce the dose.
Diarrhea Exclude other possible causes of diarrhea.
In mild diarrhea, use oral hydration and antidiarrheal agents (for example, loperamide, diphenoxylate).
In severe diarrhea, use hospitalization and intravenous hydration; interruption of treatment with sunitinib or 
sorafenib is recommended. (Restore treatment when diarrhea reaches grade 1 or stools have returned to baseline.)
Nausea and vomiting Use common oral antiemetics for treatment and prevention.
Use haloperidol and 5-hydroxytryptamine3 antagonists with sunitinib cautiously (possible QT prolongation).
Hand–foot syndrome
(h f s )
Before start of treatment, manicure and pedicure are recommended.
Prophylactic use of cream containing urea is recommended during treatment.
In mild h f s , use topical treatments: urea 40% cream, tazarotene 0.1%, topical fluorouracil, moisturizers, corti-
costeroids, shock absorbers.
In severe h f s , treatment with sunitinib or sorafenib should be interrupted until recovery to grade 1 status, and 
then dose should be reduced.
Skin rash In mild rash, use topical treatments: urea-containing lotion, fragrance-free moisturizers, topical clindamycin 
and corticosteroids (for example, hydrocortisone cream 1%).
In severe rash (rare), use systemic antibiotics (for example, oral doxycycline).
Consider dose-reduction of anticancer drugs if severe rash persists.
Hypothyroidism Thyroid-stimulating hormone (t s h) should be measured before start of treatment with sunitinib or sorafenib.
With sunitinib, t s h should be repeated every 2 months; with sorafenib, repeat t s h only if overt hypothyroidism 
occurs.
Overt and subclinical hypothyroidism should be treated.
Dose reduction with sunitinib and sorafenib is usually not required.
Hypertension Resting blood pressure should be below 140/90 mmHg before and during treatment.
Use optimal antihypertensive drugs: lisinopril, quinapril, temisartan, valsartan, atenolol, or hydrochlorothiazide 
[no cytochrome P450 (CYP) 3A4 interactions].
Use enalapril, losartan, nifedipine, and amlodipine cautiously (CYP3A4 substrates).
Avoid verapamil and diltiazem (CYP3A4 inhibitors).
In severe hypertension (above 200 mmHg systolic, above 110 mmHg diastolic), temporarily interrupt treatment 
until hypertension is controlled; restart sunitinib or sorafenib at a lower dose.
Cardiotoxicity Blood pressure should be controlled.
Baseline and periodic assessment of electrocardiogram and left ventricular ejection fraction (l v e f ) should be 
considered in patients on sunitinib and sorafenib, especially in patients with a history of heart disease.
Interrupt or reduce the dose of sunitinib or sorafenib in patients without clinical symptoms of congestive heart 
failure (c h f ), but with l v e f  below 50% or more than 20% below baseline.
In c h f , discontinue sunitinib or sorafenib, and start therapy for heart failure.
Use sunitinib cautiously with drugs and conditions that prolong QT.
Interstitial pneumonitis Radiographic changes without symptoms: continue temsirolimus and follow patient closely.
In symptomatic interstitial pneumonitis, lung imaging and pulmonary functional tests are required. With mild 
symptoms, interrupt temsirolimus until symptoms resolve; with severe symptoms, discontinue temsirolimus and 
start treatment with oral high-dose steroids (for example, prednisone 1 mg/kg)
Laboratory toxicities Hyperglycemia: fasting blood sugar should be tested before and during the treatment with temsirolimus; treat 
hyperglycemia with either or both of diet and oral agents (for example, metformin), or with insulin.
Hyperlipidemia: serum cholesterol and triglycerides should be measured before and during treatment with tem-
sirolimus. Use of statins may not be practical in this patient population. When triglycerides exceed 1000 mg/dL 
(11.3 mmol/L), consider treatment of hyperlipidemia or interrupt treatment with temsirolimus.
Elevated serum lipase and amylase: serum lipase and amylase should be followed. Do not discontinue treatment 
with sunitinib or sorafenib if enzymes are elevated in the absence of clinical symptoms and signs of pancreatitis.
Hypophosphatemia: serum phosphate levels should be measured regularly. In hypophosphatemia consider oral 
phosphate replacement (for example, sodium acid phosphate).
 SERUGA et al.
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4.2.2  Nausea and Vomiting
Nausea and vomiting occurred, respectively, in 44% 
and 24% of patients on sunitinib and in 23% and 16% 
on sorafenib; severe nausea and vomiting occurred 
in 6% of patients only 1,2.
Common antiemetics can be used, including 
prophylactically, to relieve nausea and vomiting. An-
tiemetics such as haloperidol and 5-hydroxytryptam-
ine3 antagonists can be associated with QT interval 
prolongation 19 and should be used cautiously in 
combination with sunitinib (see “Cardiotoxicity” 
later in this article).
Any constipation should be corrected (Table iii).
4.3  Skin Toxicity
Skin toxicity typically occurs in the first few weeks of 
treatment with sunitinib and sorafenib 20,21. Various 
skin changes may be observed, including hand–foot 
syndrome (h f s ).
The most clinically significant skin toxicity, h f s , 
may lead to dose modification or discontinuation of 
treatment. Discontinuation of treatment in skin toxici-
ties should be considered after the fourth occurrence 
of a grade 2 skin toxicity or the third occurrence of a 
grade 3 skin toxicity 12.
In a pooled analysis, h f s  occurred in 19% (5% 
severe) of patients on sunitinib 22. No reports of h f s  
have been seen with temsirolimus. Pre-existing 
hyperkeratosis confers a predisposition for h f s , and 
preventive manicure and pedicure are recommended. 
Topical treatment with keratolytics such as urea 
40% cream, tazarotene 0.1%, or topical fluorouracil 
showed a beneficial effect in a small series of patients 
with h f s  induced by sunitinib or sorafenib 23. Mois-
turizers, shock absorbers, and topical corticosteroids 
have been found useful by many. Patients should be 
encouraged to avoid tight-fitting shoes and friction 
and to apply cream containing urea to the hands and 
feet daily throughout therapy. In the cases of severe 
HFS, treatment should be interrupted until recovery 
to grade 1, and the dose at resumption should be 
reduced (Table iii).
Skin rash associated with sunitinib, sorafenib, 
and temsirolimus usually presents as low-grade 
maculopapular or seborrheic dermatitis 15,24 that 
rarely requires treatment interruption or dose 
reduction. Urea-containing lotions may be help-
ful if the skin is very dry. The dermatitis can be 
managed with the use of fragrance-free moistur-
izers and topical clindamycin or corticosteroids 
(hydrocortisone 1% cream, for instance) 15,24. In 
more severe cases, systemic antibiotics (for ex-
ample, orally administered doxycycline) can be 
used. Seborrheic-like rash with scaly areas can be 
treated with topical antifungals or steroids. Often, 
patients can attempt a re-escalation of the drug if 
a lower dose has been well tolerated for a period 
of time (Table iii).
4.4  Hypothyroidism
In observational studies with sunitinib, up to 85% 
of patients developed biochemical hypothyroidism, 
and approximately one quarter of all patients showed 
signs or symptoms of hypothyroidism that needed 
treatment 17,25. In contrast, in one observational study 
with sorafenib, biochemical hypothyroidism occurred 
in 18% of patients, and only 3% of patients had 
clinically significant hypothyroidism 26. Sunitinib-
induced hypothyroidism may develop in the first few 
weeks after initiation of treatment and can quickly 
become severe 17,27. Rarely, hyperthyroidism may 
precede development of hypothyroidism in patients 
on sunitinib 9.
With both sunitinib and sorafenib, thyroid-
stimulating hormone should be measured at baseline. 
The measurement should be repeated every 2 months 
with sunitinib, but only if symptoms and signs of 
hypothyroidism occur with sorafenib. The current 
recommendation is that overt and subclinical hy-
pothyroidism should be treated 28. With recognition 
and proper treatment of hypothyroidism, no dose 
modification of sunitinib and sorafenib should be 
required (Table iii).
4.5  Hypertension
In two recent meta-analyses of prospective clinical 
trials, 21% (7% severe) of patients on sunitinib and 
23% (6% severe) of patients on sorafenib developed 
arterial hypertension 29,30. Untreated arterial hyper-
tension may be important in the exacerbation of 
myocardial damage 31. This hypothesis is supported 
by animal studies, which show that inhibition of v e g f r  
signalling promotes transition from compensatory 
cardiac hypertrophy to heart failure in response to 
pressure overload 32,33.
Patients receiving sunitinib or sorafenib should 
be monitored closely for hypertension, which should 
be treated if necessary. Patients should be encour-
aged to monitor and record blood pressure daily at 
home. The objective of treatment is to normalize 
blood pressure (resting level below 140/90 mmHg). 
Standard hypertensive therapies are recommended 34; 
vasodilatators appear to be the most effective. Optimal 
choices are drugs not metabolized by the CYP system 
in the liver—for example, lisinopril and quinapril, 
temisartan and valsartan, atenolol and hydrochlorothi-
azide 35. Antihypertensive drugs that are substrates of 
CYP3A4—for example, enalapril, losartan, nifedipine, 
and amlodipine—are not ideal, but can be used cau-
tiously. The CYP3A4 inhibitors such as verapamil and 
diltiazem should be avoided 35. In severe hyperten-
sion (above 200 mmHg systolic or above 110 mmHg 
diastolic), treatment should be temporarily interrupted 
until hypertension is controlled; it can then be restarted 
at a lower dose. Uncontrolled hypertension should 
be controlled before sunitinib or sorafenib is started. TARGETED DRUGS IN ADVANCED KIDNEY CANCER
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Patients with known hypertension will likely need 
assessment or dose adjustments to their antihyper-
tensive drugs, or both. With proper management of 
hypertension, it is unlikely that interruption, dose 
reduction, or discontinuation of treatment will be 
required (Table iii).
4.6  Cardiotoxicity
Recent small observational studies showed symptom-
atic cardiac disease in 15%–18% of patients treated 
with sunitinib or sorafenib 36,37. Ongoing adjuvant 
trials will provide a definitive answer about the 
cardiotoxicity of these drugs; however, in everyday 
clinical practice, caution is already recommend con-
cerning this possible toxicity. Sunitinib prolongs the 
QT interval in a dose-dependent manner, an effect 
that can occasionally lead to ventricular arrhythmias 
(less than 1% of cases) 9.
Baseline and periodic assessment of electro-
cardiogram and left ventricular ejection fraction 
(l v e f ) should be considered in patients receiving 
sunitinib or sorafenib, especially in those with a 
history of heart disease. Every patient with new 
symptoms of peripheral edema, dyspnea, chest 
pain, or dizziness (although these symptoms are 
common in progressing cancer per se) should be 
assessed for cardiac disease. In the presence of 
congestive heat failure, sunitinib and sorafenib 
should be discontinued, and appropriate standard 
therapy for heart disease should be started. The 
dose of sunitinib or sorafenib should be interrupted 
or reduced in patients without clinical symptoms 
of congestive heart failure but with a l v e f  of less 
than 50% or more than 20% below baseline 9. 
Sunitinib should be used cautiously in patients 
with a known history of QT prolongation, in those 
who are using CYP3A4 inhibitors or drugs that are 
known to prolong QT, and in those with electrolyte 
disturbances 9 (Table iii).
4.7  Interstitial Pneumonitis
Interstitial pneumonitis is a potentially life-threat-
ening toxicity of temsirolimus, and patients, espe-
cially those with a history of lung disease, should 
be monitored for it. In patients with radiographic 
changes of interstitial pneumonitis but no symptoms 
(for example, dry cough, dyspnea, fever), treatment 
with temsirolimus can continue, but these patients 
should be followed closely. In patients with symp-
toms of interstitial pneumonitis, lung imaging and 
pulmonary function tests should be performed. Where 
mild symptoms are present, temsirolimus may be 
temporarily interrupted until symptoms resolve. In 
cases with severe symptoms, temsirolimus should be 
discontinued, and treatment with high-dose steroids 
(for example, 1 mg/kg prednisone) should be started. 
Tapering of the steroid dose should be considered if 
gradual improvement in symptoms and pulmonary 
function tests occur 15,16 (Table iii).
4.8  Hyperglycemia
Fasting blood sugar should be tested before and regu-
larly during treatment with temsirolimus 15. Hyperg-
lycemia may manifest as excessive thirst, increased 
urination, and blurred vision; if untreated, it may lead 
to coma. Management of hyperglycemia may include 
diet, orally administered agents for glycemic control 
(metformin, for instance), and insulin, if required 15 
(Table iii).
4.9  Hyperlipidemia
Serum cholesterol and triglycerides should be mea-
sured at baseline and regularly every 1–2 months 
during treatment with temsirolimus. If levels are 
elevated, a diet with reduced saturated fats and ad-
dition of lipid-lowering agents could be considered. 
Pravastatin is the only statin that is not a substrate 
of CYP3A4; it is the safest option in combination 
with temsirolimus 35. However, use of lipid-lowering 
medications may not be practical in this advanced 
cancer population. When triglyceride levels exceed 
1000 mg/dL (11.3 mmol/L), the risk of triglyceri-
demia-induced pancreatitis is high, and in patients 
without hepatic and renal insufficiency, fibrates 
(for example, gemfibrozil and fenofibrate) can be 
considered 38; otherwise, interruption of treatment 
is recommended (Table iii).
4.10  Hematologic and Other Laboratory Toxicities
A complete blood count should be obtained at the 
beginning of each treatment cycle. If grades 1 and 2 
hematologic toxicities (hemoglobin not lower than 
8 g/dL, leucocyte count not lower than 2000/mm3, 
and platelet count not lower than 50,000/mm3) are 
present, treatment can be continued at the same dose 
level. If grade 3 toxicity is present, the dose should 
be held until toxicity reaches grade 2 or lower, at 
which time treatment can be resumed at the same 
dose. If grade 4 toxicity is present, the dose should 
be held until toxicity reaches grade 2 or lower, at 
which time treatment can be resumed at a reduced 
dose. For symptomatic anemia, blood transfusions 
without treatment interruption and dose reduction 
may be offered.
Serum lipase and amylase should be followed, 
and consumption of alcohol should be discouraged 
if these parameters become elevated. In r c t s, clinical 
pancreatitis developed in only 3 patients (fewer than 
1%) on sorafenib 12. A diagnosis of pancreatitis should 
not be made solely on the basis of abnormal labora-
tory values 12. If a patient develops clinical symptoms 
of pancreatitis, sunitinib or sorafenib should be held 
while the symptoms are investigated (Table iii).SERUGA et al.
Cu r r e n t On C O l O g y —VO l u m e  16, Su p p l e m e n t 1
S58
Phosphate levels should be monitored before 
each treatment cycle, and in hypophosphatemia, oral 
phosphate replacement (that is, 1 tablet of sodium 
acid phosphate twice daily with meals) should be 
considered (Table iii).
5.  CONCLUSIONS
Patients with advanced kidney cancer need to be 
closely monitored for the development of drug-related 
toxicities. Development of drug-related toxicities 
(even at mild and moderate levels) should be vigor-
ously managed with supportive measures to prevent 
interruptions of treatment, dose reductions, and even-
tual development of life-threatening complications.
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